Novo Nordisk's Phase 3 STEP Young trial demonstrated that weekly semaglutide, combined with lifestyle changes, helped many children aged 6 to under 12 reduce their body mass index below the clinical obesity threshold. Despite this success, the stock price has not risen significantly, reflecting market hesitation due to concerns over long-term safety, pediatric treatment challenges, and payer coverage. The drug is not yet approved for children under 12, and adoption is expected to be gradual, starting with adolescents before younger children. The pediatric market represents a long-term growth opportunity for Novo Nordisk, but significant regulatory and societal hurdles remain.
Novo Nordisk shares are trading at USD 42.73, down 1.66% as of Sep 15, 2026, 23:31 WIB on Pluang. Despite the promising results from the STEP Young trial for pediatric obesity treatment, the stock price reflects some market caution. The company holds a substantial market cap of $192.10 billion, indicating strong investor interest amid ongoing regulatory and adoption challenges.
Novo's drug CagriSema has demonstrated a significant 25% weight loss effect in women, a promising result that could boost the company's prospects. This development is important as it may help revive investor confidence and improve the company's stock...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Novo Nordisk's experimental obesity drug CagriSema demonstrated an average 25% weight loss among adult women after 68 weeks in a new analysis following a late-stage trial. The drug, combining semaglutide and cagrilintide, also showed significant weig...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
